NRx Pharmaceuticals, Inc.

NasdaqCM NRXP

NRx Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -3.03

NRx Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) is -3.03 on January 14, 2025, a -131.23% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

NRx Pharmaceuticals, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.68 on October 22, 2024, which is 77.45% above the current Price to Earnings Ratio (P/E).
NRx Pharmaceuticals, Inc. 52-week low Price to Earnings Ratio (P/E) is -3.03 on January 14, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
NRx Pharmaceuticals, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.22.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: NRXP

NRx Pharmaceuticals, Inc.

CEO	Dr. Jonathan C. Javitt M.D., M.P.H.
IPO Date	Dec. 4, 2017
Location	United States
Headquarters	1201 Orange Street
Employees	2
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Key trends

Past 5 years